Our team is dedicated to revolutionizing the detection and early treatment of cancer and other complex diseases. Learn more about our mission: prognomiq.com

PrognomiQ is dedicated to working with the FDA to bring our innovative diagnostic products to patients. Read more on The Wall Street Journal here: wsj.com/articles/lab-t…

Check out our CEO and Founder, Philip Ma’s exclusive interview with Newsweek Investment Reports on our dedication towards early cancer detection: investmentreports.co/interview/phil…

#ICYMI last week GenomeWeb shared an article on the future of #Multiomics, featuring PrognomiQ and how we are overcoming challenges in working with multi-omics data. Check it out below!

Our #PrognomiQ team is looking forward to this year’s Am Soc for Mass Spec annual meeting in Anaheim, CA. Next week we will share 4️⃣ poster presentations and 2️⃣ talks. #ASMS2024

Attending #ASMS2024? This morning don’t miss Bruce Wilcox, Ph.D, our Chief Technology Officer, discuss more about our multicancer study with our deep unbiased plasma proteomics platform. See you there!

What an eventful time at the Am Soc for Mass Spec 2024 annual meeting last week! Our #PrognomiQ team enjoyed connecting with everyone during our presentations. #ASMS2024

Our team is dedicated to revolutionizing the detection and early treatment of cancer and other complex diseases. Learn more about our mission: prognomiq.com

Our most recent study highlights how #Multiomics can help provide patients with a noninvasive detection option for early-stage cancer. Check out our findings here: medrxiv.org/content/10.110…

Earlier this month, our team enjoyed connecting with the thoracic oncology community at this year’s #CHEST2024 meeting in Boston! Thank you, CHEST for hosting another educational event.

Today, PrognomiQ has announced the company's Series D financing of $34 million to help advance our company's development of an early detection test for #LungCancer. Learn more about this significant milestone: prognomiq.com/press-releases…

#ICYMI: PrognomiQ has raised an additional $34 million in funding. Hear more about the advancements being made in #LungCancer detection from our CEO & Founder, @Phillip Ma on @Endpoints News: prognomiq.com/news/prognomiq…

Yesterday, our own CEO and Founder, Philip Ma, spoke at the ASHG 2024 Annual Meeting to discuss the latest on our multi-omics approach to early detection testing for #LungCancer.

#DYK 46% of lung cancer cases are diagnosed at Stage 4, after the cancer has metastasized. This #LungCancerAwarenessMonth learn more about our mission and the urgent need for early #LungCancer detection here: prognomiq.com/#our-mission

Last week, we announced that we have raised an additional $34 million in funding to be used towards our mission of transforming the detection and early treatment of #LungCancer. Learn more about our early detection test in BioWorld MedTech below.

Tomorrow we will be at the 2024 CG MedTech, Diagnostics and Digital Health & Services Forum, where our CEO and Founder, Philip Ma, will be sharing the latest on our approach using multi-omics for early #LungCancer detection.

Early detection is associated with reduced lung cancer mortality, highlighting the need for earlier detection of disease, when cure rates are higher. #LungCancerAwarenessMonth

We’re excited to welcome Joel Kaufman to PrognomiQ as Chief Financial Officer. Please join us in welcoming Joel to the team! prognomiq.com/press-releases…

We believe early detection and treatment of cancer and other complex diseases can be unlocked through the insights provided by high-quality proteomics and multi-omics data.

Earlier this week, our team attended the Jefferies Global Healthcare Conference to share more about our ongoing product pipeline dedicated towards early lung-cancer detection for patients.